Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
03/2002
03/12/2002US6355646 Immunology treatment of inflammatory conditions and immune disorders septic shock
03/12/2002US6355618 Enzyme inhibitors
03/12/2002US6355617 Peptide derivatives
03/12/2002US6355614 Drugs of cyclic boroproline with carriers
03/12/2002US6355479 Insect polypeptide for use in the treatment of autoimmune diseases, allergies and cancer
03/12/2002US6355474 Generating antiproliferative agents; obtain wheat, ferment, separate, fine filter, boil, evaporate and recover dried material
03/12/2002US6355257 Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
03/12/2002US6355256 Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
03/12/2002US6355248 Method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent
03/12/2002US6355245 Glomerulonephritis,antibodies at low dosage
03/12/2002US6355241 In vivo production and delivery of erythropoietin
03/12/2002US6355238 Specific immune system modulation
03/12/2002CA2235625C Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation
03/12/2002CA2189657C Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
03/12/2002CA2064077C T cell receptor peptides as therapeutics for autoimmune and malignant disease
03/12/2002CA2023895C Hypoallergenic milk products and process of making
03/07/2002WO2002018623A2 Methods and reagents for protease inhibition
03/07/2002WO2002018619A2 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response
03/07/2002WO2002018593A2 Modulation of fas and fasl expression
03/07/2002WO2002018585A2 Packaging of positive-strand rna virus replicon particles
03/07/2002WO2002018583A2 Modified polypeptides stabilized in a desired conformation and methods for producing same
03/07/2002WO2002018581A2 G-protein coupled receptors
03/07/2002WO2002018575A2 Genes expressed in the cell cycle
03/07/2002WO2002018557A2 Human kinases
03/07/2002WO2002018553A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/07/2002WO2002018540A2 Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications
03/07/2002WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/07/2002WO2002018422A1 Amino acid substitution mutants of interleukin 13
03/07/2002WO2002018404A2 Nucleoside derivatives for the treatment of hepatitis c
03/07/2002WO2002018395A1 Phosphate derivatives as immunoregulatory agents
03/07/2002WO2002018389A2 Thienopyrimidine
03/07/2002WO2002018382A1 Pyrazolopyridine compound and pharmaceutical use thereof
03/07/2002WO2002018379A2 7-oxo pyridopyrimidines
03/07/2002WO2002018378A1 Pyrrolidine derivatives and their use as chymase inhibitor
03/07/2002WO2002018373A1 Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
03/07/2002WO2002018371A1 Nucleoside metabolism inhibitors
03/07/2002WO2002018361A2 Compounds having activity as inhibitors of cytochrome p450rai
03/07/2002WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors
03/07/2002WO2002018341A2 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
03/07/2002WO2002018335A1 Cyclic amine derivatives
03/07/2002WO2002018320A2 INHIBITORS OF α4 MEDIATED CELL ADHESION
03/07/2002WO2002018015A1 Natural, non-allergenic, immune system stimulant
03/07/2002WO2002017965A1 Medicinal compositions
03/07/2002WO2002017960A1 Vaccines against toxoplasma gondii
03/07/2002WO2002017959A2 Immunosuppression using piceatannol and a calcineurin inhibitor
03/07/2002WO2002017935A2 A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
03/07/2002WO2002017893A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets
03/07/2002WO2002017891A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
03/07/2002WO2002017881A2 Transdermal pharmaceutical delivery composition
03/07/2002WO2001093907A9 Chair
03/07/2002WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
03/07/2002WO2001089457A3 Thrombopoietin mimetics
03/07/2002WO2001078649A3 Pharmaceutical curative compound
03/07/2002WO2001077181A3 Anti-rhesus d monoclonal antibodies
03/07/2002WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists
03/07/2002WO2001074855A3 Compositions and methods for dendritic cell-based immunotherapy
03/07/2002WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia'
03/07/2002WO2001068033A3 Il-8 receptor antagonists
03/07/2002WO2001060407A3 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
03/07/2002WO2001059130A3 Proteins producing an altered immunogenic response and methods of making and using the same
03/07/2002WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using
03/07/2002WO2001058949A3 Heterologous polypeptide of the tnf family
03/07/2002WO2001057233A3 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
03/07/2002WO2001057022A3 Pyrazole compositions useful as inhibitors of erk
03/07/2002WO2001055219A3 scsCNTFR/NNT-1 FUSION PROTEIN
03/07/2002WO2001054716A3 Genetically engineered tumor cell vaccines
03/07/2002WO2001053468A3 Lipid metabolism enzymes and polynucleotides encoding them
03/07/2002WO2001051636A3 Secreted proteins
03/07/2002WO2001046231A3 Polynucleotides and polypeptides encoded thereby
03/07/2002WO2001043772A3 Method and device for producing an autologous immunization vaccine against cancerous diseases (tumour vaccine)
03/07/2002WO2001043761A3 Methods for treating and preventing damage to mucosal tissue
03/07/2002WO2001042285A3 Extracellular matrix and cell adhesion proteins as well as genes encoding them
03/07/2002WO2001034645A3 Mutated il-13 molecules and their uses
03/07/2002WO2001032888A3 Human transferase molecules
03/07/2002WO2001031008A3 Human and rat fgf-20 genes and gene expression products
03/07/2002WO2001021162A3 Treating allergic and inflammatory conditions using desloratadine
03/07/2002US20020028953 Process for preparing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetic acid
03/07/2002US20020028848 Administering orally 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE); anticoagulants; cardiovascular, respiratory, gastrointestinal, nervous and psyiatric disorders; autoimmune disease; antiinflammatory agents; bactericides; viricides
03/07/2002US20020028830 Treating proteinuria and swollen lymph node symptoms by administering an effective dose of a vitamin D analog to a patient on a diet which includes a calcium intake level of >800mg/day per 160 pound patient
03/07/2002US20020028828 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
03/07/2002US20020028817 Platelet derived growth factors (PDGF); 1,2-dimethyl-6-(2-thiophene)imidazolo(5,4-g)quinoxaline preparations for example; use treating proliferative malignant and non-malignant diseases; stents
03/07/2002US20020028812 Phenylalanine derivatives
03/07/2002US20020028803 Controlling cell apoptosis
03/07/2002US20020028784 Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
03/07/2002US20020028782 Cardiovascular disorders; nervous system disorders
03/07/2002US20020028774 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
03/07/2002US20020028772 Modulation of metabolism
03/07/2002US20020028514 Recombinant AAV vector-based transduction system and use of same
03/07/2002US20020028484 Expression vector for use in the treatment and prevention of viral diseases
03/07/2002US20020028449 26 Human secreted proteins
03/07/2002US20020028436 Suppression of leukocyte transferring in humans; administer immunoglobulins to humans, detect bound receptor, evaluate immune response
03/07/2002US20020028207 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
03/07/2002US20020028205 May be comprised of a heavily glycosylated mucin part, which mediates binding to selectins, such as PSGL-1; absorber to prevent a hyperacute rejection of a xenotransplant
03/07/2002US20020028203 T cell inhibitory receptor compositions and uses thereof
03/07/2002US20020028196 Administration of an effective amount of D-Ribose to a mammal that would benefit enhancement of the immune response.
03/07/2002US20020028190 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof
03/07/2002DE10042060A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation
03/07/2002DE10042059A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation
03/07/2002DE10042058A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation
03/07/2002DE10040933A1 Verwendung von beta-Mannosylglycerat (Firoin) und/oder Derivaten, insbesondere dem beta-Mannosylglyceramid (Firoin-A), in kosmetischen und dermatologischen Formulierungen Use of beta-mannosylglycerate (firoin) and / or derivatives, in particular the beta-mannosylglyceramide (firoin-A), in cosmetic and dermatological formulations